Abstract: Described herein are immunoassay methods for detecting and/or monitoring a cancer in a patient. In the method a biofluid sample from a patient is contacted with a monoclonal antibody that specifically binds to a C-terminal epitope of type XXVIII collagen, and the amount of binding between the monoclonal antibody and peptides in the sample is detected and determined.

Abstract: The present invention relates to an assay for detecting secreted proteome acidic and rich in cysteine (SPARC), and more specifically to its use in evaluating lung cancer.

Abstract: An assay measuring protease mediated degradation of type IV collagen and its biomarker potential for identifying cancer patients with a T-cell permissive tumor microenvironment is described.

Abstract: The present invention relates to monoclonal antibodies that target collagen type XIX and to the sequences of the complementarity-determining regions distinguishing the monoclonal antibodies. Also, the present invention relates to immunoassays and to kits employing the antibodies. The assays of the invention are used in the diagnosis and monitoring of cancer.

Abstract: The present invention provides monoclonal antibodies that target collagen type XXIII, and to immunoassays and kits employing the antibodies for detecting and quantifying the epitope. The invention also provides a method for identifying and monitoring subjects with inflammatory bowel disease.

Abstract: Provided herein is an antibody specifically reactive with an N-terminus neo-epitope of collagen type X alpha 1 in the amino acid sequence H2N-GIATKGLNGP, and its use in an immunoassay for evaluating a disease associated with collagen type X alpha 1, such as osteoarthritis.

Abstract: Disclosed herein are methods of immunoassay for detecting, in a patient sample, the third laminin-like globular domain (LG3) fragment cleaved and released from endorepellin/perlecan by bone morphogenetic protein-1 (BMP-1). Also disclosed are monoclonal antibodies and immunoassay kits for use in these methods of immunoassay, as well as the use of these methods of immunoassay for detecting and/or monitoring fibrotic kidney diseases, such as Lupus Nephritis (LN) or IgA nephropathy (IgAN), or particular levels of severity thereof.

Abstract: Provided herein are monoclonal antibodies, assay kits and immunoassay methods for quantifying anastellin fragments with a N-terminus amino acid sequence PIQWNAPQPS (SEQ ID NO: 1) in a patient biofluid sample. Also provided are methods for detecting and/or for monitoring fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) using the monoclonal antibodies.

Abstract: Described herein are monoclonal antibodies, assay kits and immumoassay methods for quantifying anastellin fragments with a N-terminus amino acid sequence PIQWNAPQPS (SEQ ID NO: 1) in a patient biofluid sample, and uses thereof for detecting and/or monitoring fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).

Abstract: Described herein are methods of immunoassay for detecting and/or monitoring cancer in a patient. A sample from the patient is contacted with denatured type III collagen. The amount of binding between the denatured type III collagen and antibodies in the sample that specifically recognise and bind to denatured type III collagen is then detected and determined, and the amount of binding is correlated with values associated with normal healthy subjects, and/or with values associated with known disease severity, and/or with values obtained from the patient at a previous time point, and/or with a predetermined cut-off value.

Abstract: A method of immunoassay for detecting in a biological sample a fragment of collagen type VII alpha 1 comprising an N- or C-terminal neo-epitope, the method comprising contacting the biological sample comprising the fragment of collagen type VII alpha 1 comprising the N- or C-terminal neo-epitope with an antibody of the invention, and determining the amount of binding of the antibody

Abstract: Described herein are immunoassays for detecting and/or monitoring cancer in a patient, comprising contacting a sample from a patient with a monoclonal antibody that specifically binds to a C-terminus amino acid sequence that corresponds to the C-terminus of type XX collagen. Also described are said monoclonal antibodies and immunoassay kits for use in carrying out said immunoassays.

Abstract: The present invention relates to monoclonal antibodies that target collagen type XIX, and to immunoassays and kits employing the antibodies. The assays of the invention can be used in the diagnosis and monitoring of cancer.

Abstract: A method of immunoassay for detecting and/or monitoring esophageal fibrosis and/or dysphagia in a patient and/or assessing the likelihood of or the severity of esophageal fibrosis and/or dysphagia in a patient by contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of the C5 domain of the ?3 chain of type VI collagen.

Abstract: Disclosed herein are monoclonal antibodies that specifically recognise and bind to a C-terminus of a peptide that is the C-terminus neo-epitope formed on cleavage of the N-terminal pro-peptide of the ?1-chain of type XI collagen at A?511?, and immunoassay methods and kits using and containing the antibodies. The immunoassay methods may be used for detecting and/or monitoring and/or assessing the severity or prognosis of diseases, such as, but not limited to, cancer.

Abstract: Described herein are monoclonal antibodies, assay kits and immumoassay methods for quantifying elastin fragments with a C-terminus amino acid sequence LPGGYGLPYT (SEQ ID NO: 1) in a patient biofluid sample, and uses thereof for detecting or quantifying fibrotic diseases such as chronic obstructive lung disease (COPD).

Abstract: The present invention relates to a sandwich immunoassay and kits for detecting in a biological sample cross-linked CTX-III, and its use in evaluating the efficacy of drugs targeting lysyl oxidases (LOXs). Cross-linked CTX-III can be used as a biomarker in diseases associated with fibrosis, including liver fibrosis, chronic intestinal disease, eosinophilic esophagitis and cancer.

Abstract: Described herein are immunoassay methods for detecting and/or monitoring a cancer in a patient by contacting a biofluid sample from a patient with a monoclonal antibody that specifically binds to a C-terminal epitope of type XXVIII collagen, and detecting and determining the amount of binding between the monoclonal antibody and peptides in the sample.

Abstract: The present invention relates to an antibody, wherein the antibody is specifically reactive with short isoform collagen type XVIII, but does not react with intermediate isoform collagen type XVIII or with long isoform collagen type XVIII. The invention also relates to the use of the antibody in a method of immunoassay for detecting or quantitating short isoform collagen type XVIII, wherein the method may be used to evaluate haemophilic disease.

Abstract: The present invention relates to a type XVI collagen assay and its use in evaluating diseases associated with type XVI collagen, in particular colorectal cancer and ulcerative colitis, and for identifying a subgroup of patients with Crohn’s disease that have (or are likely to develop) fibrostenotic strictures.